Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine
- Steven R. Goodman(corresponding author),
- Betty S. Pace,
- Kirk C. Hansen,
- Angelo D’alessandro,
- Yang Xia,
- Ovidiu Daescu
- University of Tennessee Health Science Center,
- ,
- University of Colorado Anschutz Medical Campus,
- University of Texas Health Science Center at Houston,
- University of Texas at Dallas,
- SUNY Upstate Medical University
Open access
Abstract
In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 772-781 (10 pages)Journal (Volume, Issue Number)
Experimental Biology and Medicine (Volume 241, Issue 7)Publication milestones
- Published - 04/2016
Publication status
ISSN
1535-3702Publication IDs
- Scopus: 84963593336
- PubMed: 27022133
